



December 18, 2024

NEWS RELEASE

Company name: TMS Co., Ltd.  
Name of representative: Takuro Wakabayashi, Chief Executive Officer  
(Securities code 4891; Growth Market)

**TMS to participate in Precision AQ Corporate Access Event  
During J.P.Morgan 2025 Week in San Francisco**

TMS Co., Ltd. (TSE: 4891) (the "Company"), a clinical-stage biopharmaceutical company focused on discovering and accelerating the development of transformative medicines in areas of high unmet medical need, today announced that the Company management team will be attending Precision AQ's corporate access event, coinciding with the J.P. Morgan 43<sup>rd</sup> Annual Healthcare Conference in San Francisco during January 13- 16, 2025.

Institutional investors that wish to schedule a meeting with management can submit a registration form to Precision AQ.

**Details of Precision AQ Corporate Access Event:**

**Date** Monday, Jan 13 – Thursday, Jan 16, 2025  
**Location** The Marker Hotel  
501 Geary Street, San Francisco, CA 94102  
**Registration Form** <https://www.precisionaq.com/jp-morgan>

**About TMS Co., Ltd.**

TMS Co., Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative medicines for the treatment of serious diseases in areas of high unmet medical need. The Company's pipeline consists of a family of small molecule compounds called SMTPs (*Stachybotrys Microspora* Triprenyl Phenols) derived from a fungus. TMS' lead program, TMS-007 (JX10), has demonstrated efficacy and safety in its Phase 2a study for the treatment of acute ischemic stroke. The Company's robust pipeline also includes programs in resistant or uncontrolled hypertension, acute kidney injury, and spinal cord injury. TMS continues to explore new pipeline products by leveraging its established partnerships with leading academic institutions in Japan, with the intention to build a bridge between academic discoveries and the global pharmaceutical market.

For more information about TMS, please visit <https://www.tms-japan.co.jp/en/>

**Investor and Media Contact:**

TMS IR: [ir@tms-japan.co.jp](mailto:ir@tms-japan.co.jp)

Kevin Lui / Precision AQ: [Kevin.Lui@precisionaq.com](mailto:Kevin.Lui@precisionaq.com)

End